Drug intelligence / Profile preview

cardamonin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

**Cardamonin** is a naturally occurring chalcone, chemically (E)-2′,4′-dihydroxy-6′-methoxy-chalcone (C16H14O4), predominantly isolated from Alpinia species such as Alpinia katsumadai and Alpinia conchigera[1][2][4][6]. It is characterized by anti-cancer, anti-inflammatory, and anti-platelet activities, and acts primarily by inhibiting the mammalian target of rapamycin (mTOR) signaling pathway, modulating apoptosis through upregulation of pro-apoptotic proteins (Bax, caspase-3) and downregulation of anti-apoptotic proteins (Bcl-2)[1][3]. Cardamonin suppresses the NF-κB pathway by inhibiting IκBα degradation and phosphorylation and interfering with nuclear translocation of NF-κB[2][5]. It also affects the Wnt/β-catenin signaling via proteasome-mediated degradation of β-catenin, inhibits cyclin and CDK molecules, induces cell cycle arrest, and mitigates lipogenesis by inhibiting fatty acid synthase (FASN) and reducing CPT-1 activity[1][3]. Research has utilized cardamonin in preclinical models for various cancers (breast, cervical, gastric, colon, lung, ovarian, leukemia, melanoma, multiple myeloma), inflammatory disorders, and sepsis, though it is not an approved pharmaceutical[1][3][5].

Other names
(E)-2′,4′-dihydroxy-6′-methoxy-chalconeAlpinetin chalcone(2E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-oneCardamoninCardamominCardamomin-RMCARDAMONIN(RG)(E)-Cardamonin(E)-Cardamomin
02

Targets

mTOR (Mammalian target of rapamycin kinase)STAT3 (Signal Transducer and Activator of Transcription 3)JNK (Mitogen-activated protein kinase kinase kinase family)ERKNF-κB

Beyond the preview

Go deeper on cardamonin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cardamonin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call